



## With Failed EVAR, When Is F/BEVAR The Best Treatment: Tips And Tricks For Performing It Successfully

*Andres Schanzer, MD*

November 21<sup>st</sup>, 2024  
Veith Symposium, New York, NY

## Disclosures

- Cook Medical, Phillips Imaging, Cryolife
- Research grants
- Case proctor
- Consultant

All compensation goes to UMass Memorial Foundation and none to me personally.

## Background: EVAR Failure is Common

**Predictors of Abdominal Aortic Aneurysm Sac Enlargement After Endovascular Repair**


Andres Schanzer, MD; Roy K. Greenberg, MD; Nathanael Hevelone, MPH; William P. Robinson, MD; Mohammad H. Eslami, MD; Robert J. Goldberg, PhD; Louis Messina, MD

10,228 EVAR patients (2002-2008)

**5-year post-EVAR AAA sac enlargement 41%**

31% of patients outside "most liberal" IFU


AAA sac enlargement more common in cases outside of IFU



## Background: EVAR Failure is Common

**39,996 EVAR patients.**

**"Aneurysm rupture occurred in 5.4% of patients after EVAR..."**



## US-ARC





United States Aortic Research Consortium

PS-IDE x 10

	Total n=3453	Complex AAA n=1096
Age at index procedure, mean (std)	73.5 (8.3)	75.1 (7.5)
Male sex	2423 (70)	877 (80)
Race (can select more than one)		
American Indian or Alaska Native		
Native Hawaiian or Pacific Islander		
Hispanic ethnicity		
Comorbidities		
Renal failure requiring dialysis		
Hypertension	3169 (92)	993 (91)
Current tobacco use	933 (27)	309 (28)
Prior EVAR	531 (16)	227 (24)
Technical success	3327 (97)	1068 (98)
CU LOS days, mean (std)	3.3 (5.4)	2.0 (3.4)
Total LOS days, mean (std)	6.4 (9.4)	4.8 (9.4)

## Background: FEVAR Conversion

### Technical Challenges

- Suprarenal Stents +/- Stents/Snorkels
- Angulation Stiff Limbs
- Short Main Body
- Infrarenal Devices
- Metal Artifact

### Background: FEVAR Conversion

**Fenestrated Stent-Grafts for Salvage of Prior Endovascular Abdominal Aortic Aneurysm Repair**

A. Katsargelis<sup>1</sup>, D. Yasar<sup>2,3</sup>, K. Okamoto<sup>4</sup>, J. F. Bellomo<sup>5</sup>, L. Talle<sup>6</sup>, E.L.G. Verhagen<sup>6,7</sup>

<sup>1</sup>Department of Vascular and Endovascular Surgery, Erlangen University, Germany  
<sup>2</sup>Department of Vascular Surgery, University of Virginia, USA  
<sup>3</sup>Department of Vascular Surgery, University of Michigan, USA  
<sup>4</sup>Department of Vascular Surgery, University of Michigan, USA  
<sup>5</sup>Department of Vascular Surgery, University of Michigan, USA  
<sup>6</sup>Department of Vascular Surgery, University of Michigan, USA  
<sup>7</sup>Department of Vascular Surgery, University of Michigan, USA

- Technical success in 24/26 (92%) patients
- 30 day mortality 0%
- Successful target vessel stenting 95% (70/74)

**Late rescue of proximal endograft failure using fenestrated and branched devices**

Zonia Martin, MD<sup>1</sup>, Roy K. Greenberg, MD<sup>2</sup>, Tara M. Matracci, MD<sup>3</sup>, Matthew J. Eagleton, MD<sup>4</sup>, Andrew O'Callaghan, MD<sup>5</sup>, and James Ross, MSc<sup>6</sup>, Cleveland, Ohio

- Technical success in 44/52 (85%) patients
- 30 day mortality 3.8%
- Successful target vessel stenting 92% (71/77)

### Aims:

1. Evaluate the use of fenestrated branched endovascular aortic repair (F/BEVAR) for the treatment of patients with prior EVAR failure.
2. Compare outcomes of F/BEVAR after failed EVAR to outcomes of F/BEVAR without prior EVAR.

### United States Aortic Research Consortium (ARC)

- University of Washington (Matthew Leaver)
- Mayo Clinic (Gustavo Chirinko)
- University of Massachusetts (Andrew Chirinko)
- Mass General Hospital (Mark Eagleton)
- Weill Cornell Medicine New York-Presbyterian (James S. Schroeder)
- University of North Carolina (Mark A. Farber)
- Surgical Associates of Palm Beach County (Anthony Lee)
- University of Alabama (Adam W. Beck)
- University of Texas South Western (Gordon H. Thoresen)
- University of California San Francisco (Tim Duerig)

### Methods

- Prospectively collected data from 6 Physician-Sponsored Investigational Device Exemption studies (2012-2018)
  - All consecutive procedures at each participating site
  - Juxtarenal, pararenal, and thoracoabdominal aneurysms
  - All repairs included >1 fenestration and/or branch
- Cohort was stratified according to whether the F/BEVAR procedure was performed after EVAR failure
  - Failed EVAR vs No EVAR

### Results: Study Cohort



893 patients enrolled (2012 - 2018)

161 (18%) failed EVAR

732 (82%) no EVAR

### Results: Study Cohort

	Total (n=893)	No EVAR (n=732)	Failed EVAR (n=161)	P-value
Men	622 (70)	486 (66)	136 (84)	<0.0001
Mean (SD) Age	71 (14)	71 (14)	70 (17)	0.27
<b>Comorbidities</b>				
Coronary artery disease	441 (49)	355 (49)	86 (53)	0.26
Cerebrovascular disease	306 (91)	243 (33)	63 (39)	0.15
Hypertension	809 (91)	657 (90)	152 (94)	0.07
Hyperlipidemia	655 (73)	531 (73)	124 (77)	0.24
Diabetes mellitus	126 (14)	103 (14)	23 (14)	0.94
Chronic obstructive pulmonary disease	355 (40)	291 (40)	64 (40)	0.99
Renal failure requiring dialysis	10 (1.1)	8 (1.1)	2 (1.2)	0.70
Cancer	109 (12)	94 (13)	15 (9.5)	0.22
Aneurysm size (max diameter, mm) (mean (SD))	65 (13)	64 (11)	69 (17)	<0.001





### Results: Target Vessels





3209 target visceral arteries (3.6/patient)

	Overall n = 3209	No EVAR n = 732	Failed EVAR n = 161	P value
<i>n (Percent) or Mean ± Standard Deviation</i>				
Vessels per patient	3.6 (0.7)	3.6 (0.7)	3.6 (0.7)	0.74
Fenestrations	2.4 (1.6)	2.4 (1.6)	2.4 (1.7)	0.99
Branches	1.1 (1.5)	1.0 (1.5)	1.2 (1.7)	0.15
Scallops	0.2 (0.4)	0.2 (0.4)	0.1 (0.3)	0.003

### Results: Operative Characteristics

	No EVAR n = 732	Failed EVAR n = 161	P value
Number of target vessels	3.6 (0.6)	3.6 (0.7)	0.77
Dose area product (mGy·cm²)	82842 (158925)	154572 (218543)	<0.001
Exam dose (mGy)	2924 (2987)	4753 (18304)	0.01
Volume of contrast used (mL)	111 (59)	97 (55)	0.01
Operative times (hours)			
In OR to incision	1.8 (1.3)	1.9 (1.0)	0.63
Incision to surgery end	4.6 (1.7)	5.2 (2.6)	0.002
In OR to out of room	6.7 (2.1)	6.9 (1.9)	0.30
Technical success	579 (97)	132 (99)	0.15
ICU length of stay (mean, SD)	2.9 (4.1)	2.9 (3.4)	0.88
Hospital length of stay (mean, SD)	6.1 (15)	6.8 (10)	0.57





### Background: FEVAR Conversion

#### Technical Challenges

- Suprarenal Stents +/- Stents/Snorkels
- Short Main Body Infrarenal Devices
- Angulation Stiff Limbs
- Metal Artifact

### Background: FEVAR Conversion

#### Technical Tips

- Preloaded systems help deal with metal artifact and it is significantly advantageous to start with sheath/catheter outside of the fenestration/branch
- All commercially available suprarenal stents can be traversed and allow for bridging stent graft placement
- Palmaz stents across visceral arteries can be traversed but difficult (or impossible) to get bridging stent graft to fully expand
- Prior endoanchors do not complicate the procedure
- Through and through wire can help navigate stiff angulated limbs
- Worthwhile to reline entire graft
- Seal must be obtained above an EVAR bare stent

